SPOCK2 and benign prostatic hyperplasia: In prostate cancer, SPOCK2 mRNA level was lower in contrast to benign prostate hyperplasia, and the upregulation of SPOCK2 in prostate cancer cell lines via transfection inhibited cell invasion and migration, in vitro (Liu et al. 2019).